Exposure Ethics: Does Hiv Pre-Exposure Prophylaxis Raise Ethical Problems for the Health Care Provider and Policy Maker?

Bioethics

Volumn 28, Issue 6, 2014, Pages 269-274

  Venter, Francois ^a,b   Allais, Lucy ^b,c   Richter, Marlise ^b,d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

HIV; Pre exposure; PreP; Prophylaxis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ATTITUDE; ETHICS; HEALTH CARE POLICY; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN RIGHTS; MORALITY; PRE-EXPOSURE PROPHYLAXIS; SEXUAL BEHAVIOR;

ANTI-HIV AGENTS; ATTITUDE; HEALTH POLICY; HIV; HIV INFECTIONS; HUMAN RIGHTS; HUMANS; MORALS; PRE-EXPOSURE PROPHYLAXIS; SEXUAL BEHAVIOR;

EID: 84928061134     PISSN: 02699702     EISSN: 14678519     Source Type: Journal    
DOI: 10.1111/bioe.12021     Document Type: Article

References (58)

1. J. Cohen. Breakthrough of the Year. HIV Treatment as Prevention. Science 2011; 334: 1628
2. R. Steinbrook. Preexposure Prophylaxis for HIV Infection. JAMA 2012; 308: 865-866.
3. Stop AIDS Project. undated.PrEP: Ethical questions and key concerns. Available at: http://stopaids.org/initiatives/prep-ethicalquestions- key-concerns [Accessed 16 September 2012]
4. A. Leibowitz. 2011. Effectiveness and Ethics of Widespread PrEP Dissemination. Available at: http://chipts.ucla.edu/2012/02/02/musings-of-a-researcherarleen- a-leibowitz-ph-d/ [Accessed 6 February 2013]
5. J. Cohen. AIDS Research. Complexity Surrounds HIV Prevention Advances. Science 2011; 333: 393
6. T. Myers. 2012. HIV Prevention Pill Will Do More Harm Than Good. Available at: http://www.usnews.com/opinion/ articles/2012/08/03/hiv-prevention-pill-will-do-more-harm-than-goodhiv- pill-will-give-a-false-sense-of-security [Accessed 29 September 2012]
7. D. Tuller. 2011. Questions on Tactic to Prevent H.I.V. Available at: http://www.nytimes.com/2011/10/11/health/11hiv.html?pagewanted= all [Accessed 10 October 2012]
8. L.O. Gostin & S.C. Kim. Ethical allocation of Preexposure HIV Prophylaxis. JAMA 2011; 305: 191-192
9. J.S. Jay & L.O. Gostin. Ethical Challenges of Preexposure Prophylaxis for HIV. JAMA 2012; 308: 867-868.
10. Southern African HIV Clinicians Society. Guidelines for Post exposure Prophylaxis. Southern African Journal of HIV Medicine 2008; 3: 36-45.
11. Q. Abdool Karim et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 2010; 329: 1168-1174.
12. R.M. Grant et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med 2010; 363: 2587- 2599.
13. J.M. Baeten et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med 2012; 367: 399-410
14. M.C. Thigpen et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med 2012; 367: 423-434.
15. A. van der Straten et al. Unraveling the Divergent Results of Preexposure Prophylaxis Trials for HIV Prevention. AIDS 2012; 26: F13- 19.
16. E.C. Hayden. HIV Drug-prevention Strategy Carries Risks. Nature 2011; 476: 260-261
17. A. Majid et al. The Use of Preexposure Treatments for HIV Prophylaxis. HIV AIDS (Auckl) 2012; 4: 17-28.
18. G. Mutua et al. Safety and Adherence to Intermittent Pre-exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers. PLoS One 2012; 7: e33103
19. M. Thigpen et al. 2011. Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana: Results from the TDF2 Study. In 6th IAS Conference on HIV Pathogenesis and Treatment. Rome
20. L. Van Damme et al. Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med 2012; 367: 411- 422.
21. S.S. Abdool Karim et al. Clinical Decisions. Preexposure Prophylaxis for HIV Prevention. N Engl J Med 2012; 367: 462-465
22. C.I. Okwundu et al. Antiretroviral Pre-exposure Prophylaxis (PrEP) for Preventing HIV in High-risk Individuals. Cochrane Database Syst Rev 2012; 7: CD007189
23. M.S. Cohen & L.R. Baden. Preexposure Prophylaxis for HIV-Where Do We Go from Here? N Engl J Med 2012; 367: 459-461
24. A. Wheelock et al. Views of Policymakers, Healthcare Workers and NGOs on HIV Pre-exposure Prophylaxis (PrEP): a Multinational Qualitative Study. BMJ Open 2012; 2.
25. S. McCormack et al. The British HIV Association/British Association for Sexual Health and HIV Position Statement on Pre-exposure Prophylaxis in the UK. Int J STD AIDS 2012; 23: 1-4.
26. Centres for Disease Control and Prevention. 2011. Pre-Exposure Prophylaxis (PrEP). Available at: http://www.cdc.gov/hiv/prep/ [Accessed 8 June 2012]
27. World Health Organization. 2012. Guidance on Couples HIV Testing and Counseling Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples: Recommendations for a Public Health Approach. Geneva: WHO
28. Centres for Disease Control and Prevention. 2012. CDC Issues Interim Guidance on Use of Medication to Prevent HIV Infection among Heterosexually Active Adults. Available at: http://www.cdc.gov/nchhstp/newsroom/ PrEPHeterosexuals.html [Accessed 29 September 2012]
29. Southern African HIV Clinicians Society. Southern African guidelines for the Safe Use of Pre-exposure Prophylaxis in Men Who Have Sex with Men Who Are at Risk for HIV Infection. Southern African Journal of HIV Medicine 2012; 13: 40-55.
30. M.S. Cohen et al. Antiviral Agents and HIV Prevention: Controversies, Conflicts and Consensus. AIDS 2012; 26: 1585-1598
31. G. Cairns. 2012. US Regulators Vote for Approval of PrEP by Large Majority. Available at: http://www.aidsmap.com/page/2350808/ [Accessed 6 February 2013]
32. Food and Drug Administration. 2012. FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm312210.htm [Accessed 6 February 2013]
33. L.A. Paxton et al. Pre-exposure Prophylaxis for HIV Infection: What If It Works? The Lancet 2007; 370: 89-93
34. T.B. Hallett et al. Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: a Modelling Study. PLoS Med 2011; 8: e1001123
35. C. Overs. 2009. Sex Work and the New Era of HIV Prevention and Care. Available at: http://apnsw.files.wordpress.com/2009/09/ new-era-1m.pdf [Accessed 29 September 2012].
36. D. Grady. 2012. Taking Truvada to Prevent H.I.V. Also Comes With Risks. Available at: http:// www.nytimes.com/2012/05/15/health/policy/taking-truvada-to-preventhiv- also-comes-with-risks.html [Accessed 14 May 2012]
37. A. Tripathi et al. 2012. Perceptions and Attitudes about Pre-exposure Prophylaxis (PrEP) among Seronegative Partners and the Potential of Sexual Disinhibition Associated with the Use of PrEP In XIX International AIDS Conference. Washington DC
38. S. Rothaus. 2012. Truvada Newly Approved to Help Prevent HIV infection, but is Costly and Brings its own Risks. Available at: http://miamiherald.typepad.com/ gaysouthflorida/2012/07/newly-approved-preventive-hiv-drug-truvadacostly- brings-own-risks.html [Accessed 14 May 2012]
39. J. Richens et al. Condoms and Seat Belts: the Parallels and the Lessons. Lancet 2000; 355: 400-403.
40. M. Kazatchkine. Redoubling Global Efforts to Support HIV/AIDS and Human Rights. HIV AIDS Policy Law Rev 2010; 15: 1, 67-73.
41. A. Tripathi et al. Preexposure Prophylaxis for HIV Infection: Healthcare Providers' Knowledge, Perception, and Willingness to Adopt Future Implementation in the southern US. South Med J 2012; 105: 199-206
42. A. Tripathi et al. 2012. Perceptions and Attitudes about Pre-exposure Prophylaxis (PrEP) among Seronegative Partners and the Potential of Sexual Disinhibition Associated with the Use of PrEP XIX International AIDS Conference. Washington DC.
43. M.H. Katz et al. Impact of Highly Active Antiretroviral Treatment on HIV Seroincidence among Men Who Have Sex with Men: San Francisco. Am J Public Health 2002; 92: 388-394
44. S. Bechange et al. Two-year Follow-up of Sexual Behavior among HIV-uninfected Household Members of Adults taking Antiretroviral Therapy in Uganda: No Evidence of Disinhibition. AIDS Behav 2010; 14: 816-823
45. G. Guest et al. Changes in Sexual Risk Behavior among Participants in a PrEP HIV Prevention Trial. Sex Transm Dis 2008; 35: 1002-1008
46. N. Siegfried et al. Male Circumcision for Prevention of Heterosexual Acquisition of HIV in Men. Cochrane Database Syst Rev: 2009; CD003362
47. S.P. Shrader et al. Updates in Hormonal Emergency Contraception. Pharmacotherapy 2011; 31: 887-895
48. K. Peltzer & S. Ramlagan. Safer Sexual Behaviours after 1 Year of Antiretroviral Treatment in KwaZulu-Natal, South Africa: a Prospective Cohort Study. Sex Health 2010; 7: 135-141
49. A. Liu et al. 2011. No Evidence of Sexual Risk Compensation among HIV-uninfected Men Who Have Sex with Men (MSM) Participating in a Tenofovir Pre-Exposure Prophylaxis (PrEP) Trial. In 6th IAS Conference on HIV Pathogenesis and Treatment. Rome
50. R.A. Bednarczyk et al. Sexual Activity-Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds. Pediatrics 2012; 130: 798-805
51. M.M. Cassell et al. Risk Compensation: the Achilles' Heel of Innovations in HIV Prevention? BMJ 2006; 332: 605-607.
52. Department of Health. undated. Guidelines for the Prevention of Malaria in South Africa. Pretoria.
53. D. Beasley. 2012. Use of Pill to Prevent HIV may be Limited in US. Available at: http://www.reuters.com/article/2012/09/07/us-usa-healthaids- prevention-idUSBRE88611M20120907 [Accessed 6 February 2013]
54. M.S. Cohen et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 2011; 365: 493-505
55. G.B. Gomez et al. The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. PLoS Med 2012; 9.
56. M.A. Wainberg et al. Development of Antiretroviral Drug Resistance. N Engl J Med 2011; 365: 637-646.
57. R.P. Walensky et al. The Cost-effectiveness of Pre-exposure Prophylaxis for HIV Infection in South African Women. Clin Infect Dis 2012; 54: 1504-1513.
58. J.L. Juusola et al. The Cost-effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex with Men. Ann Intern Med 2012; 156: 541-550.